Treatment of chronic hepatitis C in patients with cirrhosis.

摘要: Purpose of review This article reviews treatment options the approved and soon-to-be direct-acting antivirals (DAA)-based therapies in individuals with hepatitis C virus (HCV) cirrhosis. Recent findings DAA-based have been shown to be well tolerated effective achieving viral cure compensated decompensated Preliminary studies suggest that eradication arrests fibrosis progression could lead regression. Long-term benefits successful HCV this population translate into less frequent hepatic decompensation hepatocellular carcinoma development, improvements liver disease severity, reduction liver-related mortality, potential obviation need for transplantation. The optimization rates requires longer duration therapy and/or more complex combinations drugs, including ribavirin. Treatment decisions are guided by genotype, renal function, drug-drug interactions, severity Safety concerns paramount advanced continued vigilance hepatotoxicity other complications is warranted, especially those Summary availability high potency excellent safety profiles has transformed HCV-infected cirrhotic a group no 'difficult-to-treat'. Understanding pretreatment factors predict clinical vs. harm remains key treating population.